Skip to main content
NewslettersWatchlist

Alcon Inc(ALC-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low79.02
Day High79.60
Open:79.42
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
Barchart
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints
Business Wire
New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision
Business Wire
Alcon Announces Results of 2023 Annual General Meeting
Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
Business Wire
Alcon Announces Largest-Ever Scientific Presence at ASCRS 2023 and Expands Image-Guided Connectivity
Business Wire
Alcon Publishes Agenda for 2023 Annual General Meeting
Business Wire
Alcon’s “The Lens” Interactive Compliance Training Experience Receives Coveted Anthem Award
Business Wire
Alcon to Host 2023 Capital Markets Day
Business Wire
Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
Business Wire
Alcon Reports Fourth Quarter and Full Year 2022 Results
Business Wire
Alcon Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices
Business Wire
Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism
Business Wire
Alcon to Present at 2023 Annual J.P. Morgan Healthcare Conference
Business Wire
Alcon Prices US$1.3 Billion Senior Notes Offering
Business Wire
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
Motley Fool
2 Surprising Movers in the Stock Market Today
Business Wire
Alcon Reports Third Quarter 2022 Results
Business Wire
Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
Business Wire
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
Business Wire
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
PR Newswire
AERIE PHARMACEUTICALS - INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
Motley Fool
Why Aerie Pharmaceuticals Was Soaring So High This Week
Business Wire
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
PR Newswire
SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.
Spotlight Growth
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Business Wire
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Business Wire
Alcon Reports Second Quarter 2022 Results
Business Wire
Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for the Job with Pataday
Business Wire
Alcon Prices EUR 500.0 Million Senior Notes Offering
Business Wire
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
Business Wire
Alcon Reports First Quarter 2022 Results

Profile

Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.